- Company
- Belgium approved Expanded access of Remimazolam
- by Lee, Seok-Jun Aug 7, 2020 06:26am
- Hana Pharm announced on the 4th that the new drug anesthetic drug 'Remimazolam' was approved by the Federal Agency for Medicines and Health Products of Belgium for sympathetic use for COVID-19 critically ill patients. In recent years, the supply shortage of Propofol and Midazolam for the treatment of critically ill patients with COVID-19 h
- Policy
- Pricing settled Prevymis to get listed in Aug. at earliest
- by Kim, Jung-Ju Aug 7, 2020 06:25am
- The MSD Korea’s new drug Prevymis (letermovir) settled on a pricing negotiation with the South Korean health authority and successfully passed the biggest hurdle of the path to healthcare benefit. The novel drug helps to prevent cytomegalovirus (CMV) infection in patients who have received an allogeneic hematopoietic stem cell transplan
- Company
- AstraZeneca’s love for Korea expressed through investment
- by Lee, Seok-Jun Aug 5, 2020 06:26am
- A British-based multinational pharmaceutical company AstraZeneca is expanding its investment in the South Korean pharmaceutical industry. Recently, the company inked a deal with SK Bioscience on supplying COVID-19 vaccine as it saw the promising potential of the Korean industry. AstraZeneca’s investment on the Korean pharmaceutical indus
- Company
- Tecentriq can be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Aug 5, 2020 06:25am
- The indication for triple negative breast cancer of the immuno-cancer drug'T-Sentric' is expanding. According to the related industry, Tecentriq 850mg used for triple-negative breast cancer (TNBC) passed the drug commitee (DC) at 20 major hospitals nationwide, including the Big 5 General Hospital, including Seoul National University Hospit
- Company
- Eisai’s lifestyle app HeLpy for living the healthier life
- by Eo, Yun-Ho Aug 5, 2020 06:25am
- Eisai Korea reported their employees are enjoying the ‘Healthier HeLpy Life’ with the company’s personal lifestyle app ‘HeLpy’ launched in January. The employees health-conscious life started as the company decided to manage their health amid COVID-19, when the busy employees struggled to keep themselves healthy with restricted phys
- Company
- Indications for Keytruda·Tecentriq are actively expanding
- by Eo, Yun-Ho Aug 5, 2020 06:24am
- Expansion of indications for immunocancer drugs continues. According to the related industry, MSD Korea recently obtained the approval for the expansion of indications of inhibitor 'Keytruda (Pembrolizumab)' in head and neck cancer, and Roche Korea's PD-L1 inhibitor 'Tecentriq (Atezolizumab)' in liver cancer. Keytruda can be prescribed f
- Company
- Lurbinectedin by Boryung has been granted orphan drug
- by Lee, Seok-Jun Aug 5, 2020 06:24am
- Boryung announced on the 3rd that the new small cell lung cancer (SCLC) drug Lurbinectedin has been granted orphan drug designation from the MFDS for the treatment of patients with small cell lung cancer (SCLC) Lurbinectedin is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progressio
- Policy
- Zytiga, Mavyret and 161 items monitored for PVA negotiation
- by Lee, Hye-Kyung Aug 5, 2020 06:24am
- The South Korean health authority added Korea Otsuka Pharmaceutical’s Iclusig tablet (ponatinib hydrochloride hydrate), Jassen Korea’s Imbruvica capsule (ibrutinib), Zytiga tablet (abiraterone acetate) and Darzalex (daratumumab) as subject for the third quarter price-volume agreement (PVA) negotiation and monitoring. Merck’s Erbitux i
- Company
- COVID-19 pandemic crushes Big Pharma sales in Q2
- by An, Kyung-Jin Aug 4, 2020 05:54am
- Heavily impacted by COVID-19 pandemic, the Big Pharma’s second quarter performances have been underwhelming to say the least. As the World Health Organization (WHO) declared the COVID-19 pandemic on Mar. 11, the number of confirmed cases in the U.S. and Europe has exponentially surged and created a gap in pharmaceutical prescription. B
- Company
- Chong Kun Dang has maintained its highest performance
- by Lee, Seok-Jun Aug 4, 2020 05:54am
- Chong Kun Dang has maintained its highest performance in the past five years. During that period, the appearance was almost doubled as a large pharmaceutical company. The operating margin remained around 8% while increasing R&D. Meanwhile, R&D performance is also becoming visible. Chong Kun Dang's virtuous cycle is expected to continue as thi
